EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study

Anna C Meyer iD, Inka Albrecht iD, Lena Hasemann iD, Jana Diekmannshemke iD, Oliver Damm iD, Daniel Gensorowsky iD, Julian Witte iD, Sven R Quist, Ulrike Raap iD, Enno Schmidt iD

Journal of the European Academy of Dermatology and Venereology · 06.11.2026

DOI: 10.1111/jdv.70838 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.11.2026. Verfasst von Anna C Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi-Aventis Deutschland GmbH, Berlin, Germany. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi and Regeneron.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bullous pemphigoid (BP) is the most common autoimmune blistering disease and primarily affects older adults. As societies age and the burden of age‐related diseases increases, data on BP epidemiology, treatment patterns and healthcare burden in Germany remain limited.

Objectives

To assess BP epidemiology, clinical outcomes, healthcare utilization and economic burden in adults aged ≥ 18 years in Germany.

Methods

We analysed anonymized statutory health insurance claims from 6.8 million insured individuals (2010–2023). Annual cross‐sectional analyses estimated prevalence and incidence, extrapolated to the national population. In a matched incident cohort (BP, n = 2004; controls, n = 9950), we evaluated comorbidity, mortality, healthcare resource utilization, healthcare costs and pharmacologic management over up to 2 years. Mortality and costs were analysed using regression models adjusted for age, sex, calendar year, and comorbidity.

Results

BP prevalence tripled from 0.05 to 0.14 cases per 1000 individuals between 2010 and 2023, with the steepest increase observed among individuals aged ≥ 80 years. Annual incidence ranged from 34 to 63 cases per million inhabitants. BP patients exhibited a higher comorbidity burden than matched controls (mean Elixhauser index 5.0 vs. 3.8) and increased mortality (1‐year mortality: 18.8% vs. 6.0%; adjusted incidence rate ratio (IRR) 3.09, 95% CI: 2.71–3.52). Healthcare utilization was higher among BP patients, including physician contacts (38 vs. 22 per year) and hospital admissions (3.3 vs. 0.7 per year). Topical and systemic corticosteroids were prescribed in 75% and 72% of patients, respectively; additional therapies included doxycycline (19.7%), dapsone (15.0%) and azathioprine (14.8%). Mean total healthcare costs during the first year were €20,881 for BP patients versus €5586 for controls, mainly attributable to inpatient care.

Conclusions

BP represents a growing healthcare challenge characterized by a high comorbidity burden, increased mortality and healthcare costs. Current treatment remains reliant on systemic corticosteroids, underscoring the need for safe and effective steroid‐sparing therapies.

Schlagwörter

Stichwörter der Autor:innen

bullous pemphigoidcomorbiditydrug therapyhealthcare costsincidencemortalityprevalenceskin diseases

Autor:innen und Institutionen

  • Sanofi-Aventis Deutschland GmbH, Berlin, Germany.
  • Vandage GmbH, Bielefeld, Germany.
  • Clinic of Dermatology, Helix Medical Excellence Center Mainz, Mainz, Germany.
  • Department of Dermatology and Allergy, Klinikum Oldenburg, Oldenburg, Germany.
  • Division of Experimental Allergy and Immunodermatology, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
  • Lübecker Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.

ORCID-Profile: Anna C Meyer, Inka Albrecht, Lena Hasemann, Jana Diekmannshemke, Oliver Damm, Daniel Gensorowsky, Julian Witte, Ulrike Raap, Enno Schmidt

Förderung

  • Sanofi and Regeneron

Zitieren

APA

Meyer, A. C., Albrecht, I., Hasemann, L., Diekmannshemke, J., Damm, O., Gensorowsky, D., Witte, J., Quist, S. R., Raap, U., & Schmidt, E. (2026). Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70838

Vancouver

Meyer AC, Albrecht I, Hasemann L, Diekmannshemke J, Damm O, Gensorowsky D, et al. Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70838

BibTeX
@article{Meyer2026,
  author = {Meyer, Anna C and Albrecht, Inka and Hasemann, Lena and Diekmannshemke, Jana and Damm, Oliver and Gensorowsky, Daniel and Witte, Julian and Quist, Sven R and Raap, Ulrike and Schmidt, Enno},
  title = {Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70838}
}
Kostenlos starten →